Parkinson’s develops when cells in a particular part of the brain — called the substantia nigra — stop working properly and are lost over time. These brain cells produce a chemical called dopamine and play a central role in coordinating movement.
Symptoms start to appear when the brain can’t make enough dopamine to control movement properly.
Clinical trials are scientific studies that involve people. This kind of research is vital. It helps us learn more about how our bodies work, what goes wrong in conditions like Parkinson’s, and to road test potentially life-changing new treatments and therapies.
Without people stepping up to take part in clinical trials and studies, the medicines, therapies and support we have today simply would not exist.
During the pandemic many Parkinson’s studies and trials ground to a halt… but in 2021 many are restarting and ready to make up for lost time.
This year on International Clinical Trials Day we want…
In this blog we hear from scientists Professor Rohan de Silva and Dr Roberto Simone from University College London who led this important work and explain how these discoveries may lead to important new treatments for Parkinson’s.
There are thousands of different types of proteins in our bodies. They come in lots of shapes and sizes and are responsible for growth, development and the millions of tasks that keep us healthy.
Our cells are constantly making, processing and recycling proteins to make sure they have the right combination to do their jobs. And we have complex controls built into our…
Parkinson’s is a progressive condition. Brain cells get damaged slowly over time, and this leads to gradually worsening symptoms that get harder to manage with current treatments.
The search is on for therapies that can slow or stop the progression of Parkinson’s rather than just address symptoms.
These kinds of therapies are called ‘disease modifying’ and there are many promising new drugs and therapies currently in development.
Most scientists believe these therapies will be most effective if they are given early, when there are still plenty of working brain cells left to protect. …
We want Parkinson’s research in the UK to be inclusive and representative of everyone living with the condition.
This matters because some populations may have very different experiences of the condition and respond differently to therapies.
These differences may be due to variations in our underlying biology. A 2015 review of newly approved drugs found that about 20% were processed differently in the body and/or produced a different response in different racial or ethnic groups.
Research part-funded by Parkinson’s UK has shown it is possible to identify the condition by analysing the chemicals present on the surface of the skin. …
Parkinson’s UK is investing up to £1.2 million into a pioneering one-year project in partnership with the University of Sheffield. The project aims to take important steps towards creating a drug that can protect dopamine-producing brain cells and slow down the progression of Parkinson’s.
This important project is funded through the charity’s Parkinson’s Virtual Biotech initiative, which exists to fast-track the development of new treatments for people with Parkinson’s.
We’re delighted to be joined on the Parkinson’s UK blog by lead scientist Dr Heather Mortiboys to tell us more about this exciting research.
What are mitochondria and why could drugs…
Terazosin is a medication used to treat symptoms of an enlarged prostate and sometimes high blood pressure. It has been in use since 1985 and importantly the patent (or sole rights to sell the drug) has expired which means that it is very affordable.
In 2019, an international team of researchers first identified the potential of terazosin for treating Parkinson’s.
They found the drug was able to slow the loss of brain cells, increase dopamine levels and improve symptoms in various animal and cell models of Parkinson’s.
In a study of 150,000 people being treated for enlarged prostate, those treated…
Parkinson’s UK worked with people affected by the condition to design a simple survey to find out what aspects of Parkinson’s people with the condition most want to see improved through treatment.
The survey was shared with the charity’s Research Support Network — a community of people affected by Parkinson’s who are driving research forward.
Survey respondents were asked to list up to 3 symptoms or side effects of Parkinson’s that troubled them most.
The results — published in the Journal of Parkinson’s Disease — powerfully highlight the breadth and depth of symptoms and challenges that people with Parkinson’s deal…
When NLX-112, a drug developed by the biopharmaceutical company Neurolixis, first entered the scene it was a molecule that…
Head of Research Communications and Engagement, Parkinson’s UK